<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000305996">
  <TermName>poly-ICLC</TermName>
  <TermPronunciation>(PAH-lee ...)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance that is being studied in the treatment of cancer and for its ability to stimulate the immune system. It is made in the laboratory by combining the nucleic acid RNA with the chemicals poly-L-lysine and carboxymethyl cellulose.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000710186" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;poly-ICLC&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000710185" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;poly-ICLC&quot;" language="es" id="_4"/>
  <SpanishTermName>poly-ICLC</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento del cáncer así como por su capacidad para estimular el sistema inmunitario. Se produce en el laboratorio combinando el ácido nucleico del ARN con las sustancias químicas poli-L-lisina y carboximetilcelulosa.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2003-05-23</DateFirstPublished>
  <DateLastModified>2007-05-17</DateLastModified>
</GlossaryTerm>
